A Phase 1b dose escalation study with a Phase 2a expansion component to evaluate the safety and tolerability of ETC 1907206 in combination with dasatinib in advance hematologic malignancies

Type of Cancer
Hematological Malignancies

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase 1b dose escalation study with a Phase 2a expansion component to evaluate the safety and tolerability of ETC 1907206 in combination with dasatinib in advance hematologic malignancies

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.